SRPT · Sarepta Therapeutics, Inc. · Webcasts, Transcripts & Audio
$16.07
+0.06 (+0.37%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.72B
Shares
107.24M
Volume · Nov 13
1.33M
Avg daily vol (3M)
2.72M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Sarepta Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Sarepta Therapeutics, Inc. (SRPT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-09
Sarepta Therapeutics, Inc. (SRPT) November 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript
Revenue
$381.35M
▼ 4.5% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Sarepta Therapeutics, Inc. (SRPT) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
Positive tone
FSHD and DM1 readouts
siRNA pipeline
Elevidys regulatory submissions
Revenue
$401.25M
▼ 34.3% YoY Diluted EPS
$-0.05
▼ 102.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Sarepta Therapeutics, Inc. (SRPT) June 8, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Sarepta Therapeutics, Inc. (SRPT) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-01
Sarepta Therapeutics, Inc. (SRPT) June 1, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Positive tone
siRNA pipeline (FSHD and DM1)
Alevitus commercial stabilization and growth
Alevitus clinical evidence and disease modification
Revenue
$730.80M
▼ 1.9% YoY Diluted EPS
$2.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-03
Sarepta Therapeutics, Inc. (SRPT) March 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Positive tone
ELEVIDYS Commercial Initiatives & Guidance
Pipeline (siRNA Programs)
PMO Therapies (AMONDYS, VYONDYS, EXONDYS)
Revenue
$442.93M
▼ 32.7% YoY Diluted EPS
$-3.93
▼ 362% YoY Gross margin
-6.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
Sarepta Therapeutics, Inc. (SRPT) January 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-03
Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript
Positive tone
ESSENCE confirmatory trial results
COVID impact on trial data
Accelerated to traditional approval transition
Revenue
$399.36M
▼ 14.5% YoY Diluted EPS
$-0.50
▼ 247.1% YoY Gross margin
54.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-16
Sarepta Therapeutics, Inc. (SRPT) Q2 2025 Earnings Call Transcript
Balanced tone
ELEVIDYS label and safety update
Portfolio refocus and pipeline
ELEVIDYS revenue stress test
Revenue
$611.09M
▲ 68.4% YoY Diluted EPS
$1.89
▲ 2600% YoY Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript
Cautious tone
ELEVIDYS launch and guidance revision
Patient safety event and liver failure
Site capacity and top-site imbalance
Revenue
$744.86M
▲ 80.2% YoY Diluted EPS
$-4.60
▼ 1343.2% YoY Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call
Confident tone
ELEVIDYS launch and commercial performance
Financial performance and 2025 guidance
LGMD franchise pipeline
Revenue
$658.41M
▲ 65.9% YoY Diluted EPS
$1.50
Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
Confident tone
ELEVIDYS commercial performance
PMO franchise (EXONDYS, VYONDYS, AMONDYS)
Guidance and 2025 outlook
Revenue
$467.17M
▲ 40.8% YoY Diluted EPS
$0.34
Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript
Confident tone
ELEVIDYS label expansion and launch
Roche partnership and ex-US approvals
PMO franchise (Exondys, Vyondys, Amondys)
Revenue
$362.93M
▲ 38.9% YoY Diluted EPS
$0.07
Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
Confident tone
ELEVIDYS commercial performance
Financial results and capitalization
FDA label expansion review
Revenue
$413.46M
▲ 63.1% YoY Diluted EPS
$0.37
Gross margin
74.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
Confident tone
ELEVIDYS launch performance
Roche ex-US partnership and supply
Pipeline advancement
Revenue
$396.78M*
▲ 53.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript
Revenue
$331.82M
▲ 44.1% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript
Revenue
$261.24M
▲ 11.9% YoY Diluted EPS
$-0.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript
Revenue
$253.50M
▲ 20.2% YoY Diluted EPS
$-5.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Sarepta Therapeutics, Inc. (SRPT) Q4 2022 Earnings Call Transcript
Revenue
$258.43M*
▲ 28.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q3 2022 Earnings Call Transcript
Revenue
$230.27M
▲ 21.6% YoY Diluted EPS
$-2.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q2 2022 Earnings Call Transcript
Revenue
$233.49M
▲ 42.3% YoY Diluted EPS
$-2.65
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q1 2022 Earnings Call Transcript
Revenue
$210.83M
▲ 43.5% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Sarepta Therapeutics, Inc. (SRPT) Q4 2021 Earnings Call Transcript
Revenue
$201.46M*
▲ 38.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-15
Sarepta Therapeutics, Inc. (SRPT) Q3 2021 Earnings Call Transcript
Revenue
$189.41M
▲ 31.6% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q2 2021 Earnings Call Transcript
Revenue
$164.09M
▲ 19.5% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q1 2021 Earnings Call Transcript
Revenue
$146.93M
▲ 29.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Sarepta Therapeutics, Inc. (SRPT) Q4 2020 Earnings Call Transcript
Revenue
$145.14M
▲ 45% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q3 2020 Earnings Call Transcript
Revenue
$143.92M
▲ 45.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q2 2020 Earnings Call Transcript
Revenue
$137.36M
▲ 45.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Date not confirmed
Sarepta Therapeutics, Inc. (SRPT) Q1 2020 Earnings Call Transcript
Revenue
$113.67M
▲ 30.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–34 of 34 webcasts
Key facts
CIK
873303
CUSIP
803607100
13F (30d)
247 filings
215 filers
Visit website
Investor relations